ARS Pharmaceuticals (SPRY) Other Accumulated Expenses (2024 - 2026)

ARS Pharmaceuticals (SPRY) has 3 years of Other Accumulated Expenses data on file, last reported at $592000.0 in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses changed N/A year-over-year to $592000.0; the trailing twelve-month figure through Mar 2026 stood at $592000.0 (changed N/A YoY), and the FY2025 full-year result was $588000.0, up 1300.0% from the prior year.
• Other Accumulated Expenses improved to $592000.0 in Q1 2026, from $588000.0 in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $3.1 million in Q3 2025 to a low of $42000.0 in Q4 2024.
• A 3-year average of $1.1 million and a median of $590000.0 in 2025 frame the typical range for Other Accumulated Expenses.
• Peak annual rise in Other Accumulated Expenses reached 1300.0% in 2025, while the deepest fall reached 1300.0% in 2025.
• Tracing SPRY's Other Accumulated Expenses over 3 years: stood at $42000.0 in 2024, then surged by 1300.0% to $588000.0 in 2025, then climbed by 0.68% to $592000.0 in 2026.
• Business Quant data shows SPRY's Other Accumulated Expenses at $592000.0 in Q1 2026, $588000.0 in Q4 2025, and $3.1 million in Q3 2025.